Clinical multi-omics strategies for the effective cancer management

Journal of Proteomics

Volumn 188, Issue , 2018, Pages 97-106

  Yoo, Byong Chul ^a   Kim, Kyung Hee ^a   Woo, Sang Myung ^a   Myung, Jae Kyung ^b  

^a National Cancer Center   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Biomarker discovery; Cancer; Omics strategy; Predictive, preventive, and personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; TRANSCRIPTOME;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER PROGNOSIS; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; GENE MUTATION; GENOMICS; HUMAN; MALIGNANT NEOPLASM; METABOLOMICS; OMICS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEOGENOMICS; PROTEOMETABOLOMIC; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; URINE; DISEASE MANAGEMENT; NEOPLASM; PROCEDURES;

DISEASE MANAGEMENT; GENOMICS; HUMANS; NEOPLASMS; PRECISION MEDICINE; PROTEOMICS;

EID: 85027577153     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2017.08.010     Document Type: Review

References (148)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2017. CA Cancer J. Clin. 67 (2017), 7–30.
2. Doll, R., Peto, R., The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl. Cancer Inst. 66 (1981), 1191–1308.
3. Fouad, Y.A., Aanei, C., Revisiting the hallmarks of cancer. Am. J. Cancer Res. 7 (2017), 1016–1036.
4. Hu, R., Wang, X., Zhan, X., Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J., 4(2), 2013 (5085-4-2).
5. Xue, Y., Lameijer, E.W., Ye, K., Zhang, K., Chang, S., Wang, X., Wu, J., Gao, G., Zhao, F., Li, J., Han, C., Xu, S., Xiao, J., Yang, X., Ying, X., Zhang, X., Chen, W.H., Liu, Y., Zhang, Z., Huang, K., Yu, J., Precision medicine: what challenges are we facing?. Genomics Proteomics Bioinformatics 14 (2016), 253–261.
6. Golubnitschaja, O., Costigliola, V., EPMA, General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J., 3(14), 2012 (5085-3-14).
7. https://obamawhitehouse.archives.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision -medicine-initiative.
8. https://www.whitehouse.gov/blog/2015/01/21/precision-medicine-improving-health-and-treating-disease.
9. Golubnitschaja, O., Costigliola, V., EPMA, EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J., 6(4), 2015 (015-0026-2. eCollection 2015).
10. Lemke, H.U., Golubnitschaja, O., Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within ‘Horizon 2020’. EPMA J., 5(8), 2014 (5085-5-8. eCollection 2014).
11. Golubnitschaja, O., Baban, B., Boniolo, G., Wang, W., Bubnov, R., Kapalla, M., Krapfenbauer, K., Mozaffari, M.S., Costigliola, V., Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J., 7, 2016, 23.
12. Coyne, G.O., Takebe, N., Chen, A.P., Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr. Probl. Cancer 41 (2017), 182–193.
13. Tsimberidou, A.M., Initiative for molecular profiling and advanced cancer therapy and challenges in the implementation of precision medicine. Curr. Probl. Cancer 41 (2017), 176–181.
14. Golubnitschaja, O., Feeling cold and other underestimated symptoms in breast cancer: anecdotes or individual profiles for advanced patient stratification?. EPMA J. 8 (2017), 17–22.
15. Bubnov, R., Polivka, J. Jr., Zubor, P., Konieczka, K., Golubnitschaja, O., “Pre-metastatic niches” in breast cancer: are they created by or prior to the tumour onset? “Flammer syndrome” relevance to address the question. EPMA J. 8 (2017), 141–157.
16. Yoo, B.C., Yeo, S.G., Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: a review. EPMA J. 8 (2017), 61–67.
17. Avishai, E., Yeghiazaryan, K., Golubnitschaja, O., Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine. EPMA J. 8 (2017), 23–33.
18. Kinkorova, J., Biobanks in the era of personalized medicine: objectives, challenges, and innovation: overview. EPMA J., 7(4), 2016 (016-0053-7. eCollection 2015).
19. Overman, M.J., Modak, J., Kopetz, S., Murthy, R., Yao, J.C., Hicks, M.E., Abbruzzese, J.L., Tam, A.L., Use of research biopsies in clinical trials: are risks and benefits adequately discussed?. J. Clin. Oncol. 31 (2013), 17–22.
20. Best, M.G., Vancura, A., Wurdinger, T., Platelet RNA as a circulating biomarker trove for cancer diagnostics. J. Thromb. Haemost. 15 (2017), 1295–1306.
21. Bielcikova, Z., Jakabova, A., Pinkas, M., Zemanova, M., Kolostova, K., Bobek, V., Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?. Am. J. Transl. Res. 9 (2017), 2807–2823.
22. Kanikarla-Marie, P., Lam, M., Menter, D.G., Kopetz, S., Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev., 2017.
23. Janyasupab, M., Lee, Y.H., Zhang, Y., Liu, C.W., Cai, J., Popa, A., Samia, A.C., Wang, K.W., Xu, J., Hu, C.C., Wendt, M.K., Schiemann, B.J., Thompson, C.L., Yen, Y., Schiemann, W.P., Liu, C.C., Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples. Recent Pat. Biomark 5 (2015), 93–100.
24. Lourenco, A.P., Benson, K.L., Henderson, M.C., Silver, M., Letsios, E., Tran, Q., Gordon, K.J., Borman, S., Corn, C., Mulpuri, R., Smith, W., Alpers, J., Costantini, C., Rohatgi, N., Yang, R., Haythem, A., Biren, S., Morris, M., Kass, F., Reese, D.E., A noninvasive blood-based combinatorial proteomic biomarker assay to detect breast cancer in women under the age of 50 years. Clin. Breast Cancer, 2017.
25. Di Cello, A., Di Sanzo, M., Perrone, F.M., Santamaria, G., Rania, E., Angotti, E., Venturella, R., Mancuso, S., Zullo, F., Cuda, G., Costanzo, F., DJ-1 is a reliable serum biomarker for discriminating high-risk endometrial cancer. Tumour Biol., 39, 2017 (1010428317705746).
26. Schrump, D.S., Circulating tumor DNA: solid data from liquid biopsies. J. Thorac. Cardiovasc. Surg., 2017.
27. Han, X., Wang, J., Sun, Y., Circulating tumor DNA as biomarkers for cancer detection. Genomics Proteomics Bioinformatics 15 (2017), 59–72.
28. Scholer, L.V., Reinert, T., Orntoft, M.W., Kassentoft, C.G., Arnadottir, S.S., Vang, S., Nordentoft, I., Knudsen, M., Lamy, P., Andreasen, D., Mortensen, F.V., Knudsen, A.R., Stribolt, K., Sivesgaard, K., Mouritzen, P., Nielsen, H.J., Laurberg, S., Orntoft, T.F., Andersen, C.L., Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin. Cancer Res., 2017, 10.1158/1078-0432.CCR-17-0510 [Epub ahead of print].
29. Alama, A., Coco, S., Vanni, I., Grossi, F., Reply to the letter to the editor by C. Nicolazzo et al.: “circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung Cancer patients treated with first-line chemotherapy”. Int. J. Mol. Sci., 18, 2017, 10.3390/ijms18061309.
30. Iijima, Y., Hirotsu, Y., Amemiya, K., Higashi, S., Miyashita, Y., Omata, M., Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. Respir. Med. Case Rep. 22 (2017), 31–33.
31. van Ginkel, J.H., Huibers, M.M.H., van Es, R.J.J., de Bree, R., Willems, S.M., Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer, 17(428), 2017 (017-3424-0).
32. Shu, Y., Wu, X., Tong, X., Wang, X., Chang, Z., Mao, Y., Chen, X., Sun, J., Wang, Z., Hong, Z., Zhu, L., Zhu, C., Chen, J., Liang, Y., Shao, H., Shao, Y.W., Circulating tumor DNA mutation profiling by targeted next generation sequencing provides guidance for personalized treatments in multiple cancer types. Sci Rep, 7(583), 2017 (017-00520-1).
33. Hahn, A.W., Gill, D.M., Maughan, B., Agarwal, A., Arjyal, L., Gupta, S., Streeter, J., Bailey, E., Pal, S.K., Agarwal, N., Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget 8 (2017), 33614–33620.
34. Sefrioui, D., Beaussire, L., Perdrix, A., Clatot, F., Michel, P., Frebourg, T., Di Fiore, F., Sarafan-Vasseur, N., Direct circulating tumor DNA detection from unpurified plasma using a digital PCR platform. Clin. Biochem., 2017, 10.1016/j.clinbiochem.2017.06.005 [Epub ahead of print].
35. Bernabe, R., Hickson, N., Wallace, A., Blackhall, F.H., What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?. Eur. J. Cancer 81 (2017), 66–73.
36. Lacombe, J., Brooks, C., Hu, C., Menashi, E., Korn, R., Yang, F., Zenhausern, F., Analysis of saliva gene expression during head and neck cancer radiotherapy: a pilot study. Radiat. Res. 188 (2017), 75–81.
37. Liu, H.J., Guo, Y.Y., Li, D.J., Predicting novel salivary biomarkers for the detection of pancreatic cancer using biological feature-based classification. Pathol. Res. Pract. 213 (2017), 394–399.
38. Ohshima, M., Sugahara, K., Kasahara, K., Katakura, A., Metabolomic analysis of the saliva of Japanese patients with oral squamous cell carcinoma. Oncol. Rep. 37 (2017), 2727–2734.
39. Khyani, I.A.M., Qureshi, M.A., Mirza, T., Farooq, M.U., Detection of interleukins-6 and 8 in saliva as potential biomarkers of oral pre-malignant lesion and oral carcinoma: a breakthrough in salivary diagnostics in Pakistan. Pak. J. Pharm. Sci. 30 (2017), 817–823.
40. Hagan, S., Martin, E., Enriquez-de-Salamanca, A., Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. EPMA J., 7(15), 2016 (016-0065-3. eCollection 2016).
41. Bohm, D., Keller, K., Pieter, J., Boehm, N., Wolters, D., Siggelkow, W., Lebrecht, A., Schmidt, M., Kolbl, H., Pfeiffer, N., Grus, F.H., Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach. Oncol. Rep. 28 (2012), 429–438.
42. Iannone, A., Losurdo, G., Pricci, M., Girardi, B., Massaro, A., Principi, M., Barone, M., Ierardi, E., Di Leo, A., Stool investigations for colorectal cancer screening: from occult blood test to DNA analysis. J. Gastrointest. Cancer 47 (2016), 143–151.
43. Finney Rutten, L.J., Jacobson, R.M., Wilson, P.M., Jacobson, D.J., Fan, C., Kisiel, J.B., Sweetser, S., Tulledge-Scheitel, S.M., St Sauver, J.L., Early adoption of a multitarget stool DNA test for colorectal cancer screening. Mayo Clin. Proc. 92 (2017), 726–733.
44. Herring, E., Kanaoka, S., Tremblay, E., Beaulieu, J.F., Droplet digital PCR for quantification of ITGA6 in a stool mRNA assay for the detection of colorectal cancers. World J. Gastroenterol. 23 (2017), 2891–2898.
45. Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J.S., Kong, X., Koya, R.C., Flaherty, K.T., Chapman, P.B., Kim, M.J., Hayward, R., Martin, M., Yang, H., Wang, Q., Hilton, H., Hang, J.S., Noe, J., Lambros, M., Geyer, F., Dhomen, N., Niculescu-Duvaz, I., Zambon, A., Niculescu-Duvaz, D., Preece, N., Robert, L., Otte, N.J., Mok, S., Kee, D., Ma, Y., Zhang, C., Habets, G., Burton, E.A., Wong, B., Nguyen, H., Kockx, M., Andries, L., Lestini, B., Nolop, K.B., Lee, R.J., Joe, A.K., Troy, J.L., Gonzalez, R., Hutson, T.E., Puzanov, I., Chmielowski, B., Springer, C.J., GA, McArthur, Sosman, J.A., Lo, R.S., Ribas, A., Marais, R., RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366 (2012), 207–215.
46. Chevli, K.K., Duff, M., Walter, P., Yu, C., Capuder, B., Elshafei, A., Malczewski, S., Kattan, M.W., Jones, J.S., Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy. J. Urol. 191 (2014), 1743–1748.
47. Schmid, M., Hansen, J., Chun, F.K., Urinary prostate cancer antigen 3 as a tumour marker: biochemical and clinical aspects. Adv. Exp. Med. Biol. 867 (2015), 277–289.
48. Wang, T., Qu, X., Jiang, J., Gao, P., Zhao, D., Lian, X., Li, X., Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer. Oncotarget, 2017.
49. Loeb, S., Bruinsma, S.M., Nicholson, J., Briganti, A., Pickles, T., Kakehi, Y., Carlsson, S.V., Roobol, M.J., Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification. Eur. Urol. 67 (2015), 619–626.
50. Birnbaum, J.K., Feng, Z., Gulati, R., Fan, J., Lotan, Y., Wei, J.T., Etzioni, R., Projecting benefits and harms of novel cancer screening biomarkers: a study of PCA3 and prostate cancer. Cancer Epidemiol. Biomark. Prev. 24 (2015), 677–682.
51. Chan, J., Roach, M., Words of wisdom. Re: genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. Eur. Urol. 69 (2016), 539–540.
52. Den, R.B., Yousefi, K., Trabulsi, E.J., Abdollah, F., Choeurng, V., Feng, F.Y., Dicker, A.P., Lallas, C.D., Gomella, L.G., Davicioni, E., Karnes, R.J., Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J. Clin. Oncol. 33 (2015), 944–951.
53. Isbarn, H., Giannarini, G., Re: genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. Eur. Urol. 68 (2015), 337–338.
54. Dalela, D., Loppenberg, B., Sood, A., Sammon, J., Abdollah, F., Contemporary role of the decipher(R) test in prostate cancer management: current practice and future perspectives. Rev. Urol. 18 (2016), 1–9.
55. Sedelaar, J.P., Schalken, J.A., The need for a personalized approach for prostate cancer management. BMC Med., 13(109), 2015 (015-0344-1).
56. Rakha, E.A., Reis-Filho, J.S., Baehner, F., Dabbs, D.J., Decker, T., Eusebi, V., Fox, S.B., Ichihara, S., Jacquemier, J., Lakhani, S.R., Palacios, J., Richardson, A.L., Schnitt, S.J., Schmitt, F.C., Tan, P.H., Tse, G.M., Badve, S., Ellis, I.O., Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res., 12, 2010, 207.
57. Fang, B., Mehran, R.J., Heymach, J.V., Swisher, S.G., Predictive biomarkers in precision medicine and drug development against lung cancer. Chin. J. Cancer 34 (2015), 295–309.
58. Shiraishi, H., Fujiwara, Y., Kakuya, T., Tsuta, K., Motoi, N., Miura, N., Watabe, Y., Watanabe, S.I., Noro, R., Nagashima, K., Huang, W., Yamada, T., Asamura, H., Ohe, Y., Honda, K., Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. Biomark. Med, 2017.
59. Polivka, J.J., Kralickova, M., Polivka, J., Kaiser, C., Kuhn, W., Golubnitschaja, O., Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon?. EPMA J. 8 (2017), 119–127.
60. Onaindia, A., Medeiros, L.J., Patel, K.P., Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod. Pathol., 2017.
61. Kuroda, D., Sawayama, H., Kurashige, J., Iwatsuki, M., Eto, T., Tokunaga, R., Kitano, Y., Yamamura, K., Ouchi, M., Nakamura, K., Baba, Y., Sakamoto, Y., Yamashita, Y., Yoshida, N., Chikamoto, A., Baba, H., Controlling Nutritional Status (CONUT) score is a prognostic marker for gastric cancer patients after curative resection. Gastric Cancer, 2017.
62. Parry, C.D., Patra, J., Rehm, J., Alcohol consumption and non-communicable diseases: epidemiology and policy implications. Addiction 106 (2011), 1718–1724.
63. Grech, G., Zhan, X., Yoo, B.C., Bubnov, R., Hagan, S., Danesi, R., Vittadini, G., Desiderio, D.M., EPMA position paper in cancer: current overview and future perspectives. EPMA J., 6(9), 2015 (015-0030-6. eCollection 2015).
64. Maleva, I., Madjunkova, S., Bozhinovski, G., Smickova, E., Kondov, G., Spiroski, Z., Arsovski, A., Plaseska-Karanfilska, D., Genetic variation of the brca1 and brca2 genes in macedonian patients. Balkan J Med Genet 15 (2012), 81–85.
65. Germini, D., Gehrke, F., Lira, D., Alves, B., Azzalis, L., Perez, M., Fonseca, F., Waisberg, J., HMSH2 and HMSH6 gene expression profiles in colorectal adenocarcinoma in patients up to 50 years of age. Biomed Pharmacother 83 (2016), 602–606.
66. Yan, Z.H., Cui, L.H., Wang, X.H., Li, C., He, X., Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer. World J. Gastroenterol. 20 (2014), 18338–18345.
67. Barry, M.J., Simmons, L.H., Prevention of prostate cancer morbidity and mortality: primary prevention and early detection. Med. Clin. North Am. 101 (2017), 787–806.
68. Shoaibi, A., Rao, G.A., Cai, B., Rawl, J., Haddock, K.S., Hebert, J.R., Prostate specific antigen-growth curve model to predict high-risk prostate cancer. Prostate 77 (2017), 173–184.
69. Hiraoka, A., Ishimaru, Y., Kawasaki, H., Aibiki, T., Okudaira, T., Toshimori, A., Kawamura, T., Yamago, H., Nakahara, H., Suga, Y., Azemoto, N., Miyata, H., Miyamoto, Y., Ninomiya, T., Hirooka, M., Abe, M., Matsuura, B., Hiasa, Y., Michitaka, K., Tumor markers AFP, AFP-L3, and DCP in hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Oncology 89 (2015), 167–174.
70. Wang, C.H., Wey, K.C., Mo, L.R., Chang, K.K., Lin, R.C., Kuo, J.J., Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 16 (2015), 3595–3604.
71. Go, V.L., Carcinoembryonic antigen: clinical application. Cancer 37 (1976), 562–566.
72. Setoyama, T., Natsugoe, S., Okumura, H., Matsumoto, M., Uchikado, Y., Ishigami, S., Owaki, T., Takao, S., Aikou, T., Carcinoembryonic antigen messenger RNA expression in blood predicts recurrence in esophageal cancer. Clin. Cancer Res. 12 (2006), 5972–5977.
73. Shinkins, B., Nicholson, B.D., James, T., Pathiraja, I., Pugh, S., Perera, R., Primrose, J., Mant, D., What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. Health Technol. Assess. 21 (2017), 1–60.
74. Barnett, D., Liu, Y., Partyka, K., Huang, Y., Tang, H., Hostetter, G., Brand, R.E., Singhi, A.D., Drake, R.R., Haab, B.B., The CA19-9 and sialyl-TRA antigens define separate subpopulations of pancreatic cancer cells. Sci Rep, 7(4020), 2017 (017-04164-z).
75. Joo, J.G., Ladi, S., Nagy, B.Z., Langmar, Z., Management of hereditary ovarian cancer. Orv. Hetil. 152 (2011), 1596–1608.
76. Raamanathan, A., Simmons, G.W., Christodoulides, N., Floriano, P.N., Furmaga, W.B., Redding, S.W., Lu, K.H., Bast, R.C. Jr., McDevitt, J.T., Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. Cancer Prev. Res. (Phila.) 5 (2012), 706–716.
77. Liao, J.B., Viruses and human cancer. Yale J. Biol. Med. 79 (2006), 115–122.
78. Yutani, S., Ueshima, K., Abe, K., Ishiguro, A., Eguchi, J., Matsueda, S., Komatsu, N., Shichijo, S., Yamada, A., Itoh, K., Sasada, T., Kudo, M., Noguchi, M., Phase II study of personalized peptide vaccination with both a hepatitis C virus-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients. J Immunol Res, 2015, 2015, 473909.
79. Stewart, B.W., Bray, F., Forman, D., Ohgaki, H., Straif, K., Ullrich, A., Wild, C.P., Cancer prevention as part of precision medicine: ‘plenty to be done’. Carcinogenesis 37 (2016), 2–9.
80. Golubnitschaja, O., Kinkorova, J., Costigliola, V., Predictive, Preventive and Personalised Medicine as the hardcore of ‘Horizon 2020’: EPMA position paper. EPMA J., 5(6), 2014 (5085-5-6).
81. Tomlinson, B., Lazarus, H.M., Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making. Expert. Rev. Hematol. 10 (2017), 563–574.
82. Lih, C.J., Takebe, N., Considerations of developing an NGS assay for clinical applications in precision oncology: the NCI-MATCH NGS assay experience. Curr. Probl. Cancer 41 (2017), 201–211.
83. Mardis, E.R., Next-generation sequencing platforms. Annu Rev Anal Chem (Palo Alto, Calif) 6 (2013), 287–303.
84. Meyerson, M., Gabriel, S., Getz, G., Advances in understanding cancer genomes through second-generation sequencing. Nat. Rev. Genet. 11 (2010), 685–696.
85. Dong, L., Wang, W., Li, A., Kansal, R., Chen, Y., Chen, H., Li, X., Clinical next generation sequencing for precision medicine in cancer. Curr. Genomics 16 (2015), 253–263.
86. Lehmann-Che, J., Poirot, B., Boyer, J.C., Evrard, A., Cancer genomics guide clinical practice in personalized medicine. Therapie, 2017, 10.1016/j.therap.2016.09.015 [Epub ahead of print].
87. Lupini, L., Bassi, C., Mlcochova, J., Musa, G., Russo, M., Vychytilova-Faltejskova, P., Svoboda, M., Sabbioni, S., Nemecek, R., Slaby, O., Negrini, M., Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients. BMC Cancer, 15(808), 2015 (015-1752-5).
88. Griewank, K.G., Schilling, B., Next-generation sequencing to guide treatment of advanced melanoma. Am. J. Clin. Dermatol. 18 (2017), 303–310.
89. Lee, H., Ross, J.S., The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. Ther. Adv. Gastroenterol. 10 (2017), 507–520.
90. Johnson, B., Cooke, L., Mahadevan, D., Next generation sequencing identifies ‘interactome’ signatures in relapsed and refractory metastatic colorectal cancer. J. Gastrointest. Oncol. 8 (2017), 20–31.
91. Weiss, G.J., Byron, S.A., Aldrich, J., Sangal, A., Barilla, H., Kiefer, J.A., Carpten, J.D., Craig, D.W., Whitsett, T.G., A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. PLoS One, 12, 2017, e0179170.
92. Hidaka, N., Iwama, E., Kubo, N., Harada, T., Miyawaki, K., Tanaka, K., Okamoto, I., Baba, E., Akashi, K., Sasaki, H., Nakanishi, Y., Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Lung Cancer 108 (2017), 75–82.
93. Reifenberger, G., Wirsching, H.G., Knobbe-Thomsen, C.B., Weller, M., Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat. Rev. Clin. Oncol. 14 (2017), 434–452.
94. Goodwin, S., McPherson, J.D., McCombie, W.R., Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17 (2016), 333–351.
95. Zhu, S., Qing, T., Zheng, Y., Jin, L., Shi, L., Advances in single-cell RNA sequencing and its applications in cancer research. Oncotarget, 2017, 10.18632/oncotarget.17893 [Epub ahead of print].
96. Kim, K.T., Lee, H.W., Lee, H.O., Song, H.J., Jeong da, E., Shin, S., Kim, H., Shin, Y., Nam, D.H., Jeong, B.C., Kirsch, D.G., Joo, K.M., Park, W.Y., Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol., 17(80), 2016 (016-0945-9).
97. Sharon, D., Tilgner, H., Grubert, F., Snyder, M., A single-molecule long-read survey of the human transcriptome. Nat. Biotechnol. 31 (2013), 1009–1014.
98. Zheng, C., Zheng, L., Yoo, J.K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J.Y., Zhang, Q., Liu, Z., Dong, M., Hu, X., Ouyang, W., Peng, J., Zhang, Z., Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell, 169(1342), 2017 (1356.e16).
99. Chung, W., Eum, H.H., Lee, H.O., Lee, K.M., Lee, H.B., Kim, K.T., Ryu, H.S., Kim, S., Lee, J.E., Park, Y.H., Kan, Z., Han, W., Park, W.Y., Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat. Commun., 8, 2017, 15081.
100. Lee, H.O., Park, W.Y., Single-cell RNA-seq unveils tumor microenvironment. BMB Rep. 50 (2017), 283–284.
101. Liu, X., Meltzer, S.J., Gastric cancer in the era of precision medicine. Cell. Mol. Gastroenterol. Hepatol. 3 (2017), 348–358.
102. Liu, Y., Yin, X., Zhong, J., Guan, N., Luo, Z., Min, L., Yao, X., Bo, X., Dai, L., Bai, H., Systematic identification and assessment of therapeutic targets for breast cancer based on genome-wide RNA interference transcriptomes. Genes (Basel), 8, 2017, 10.3390/genes8030086.
103. Li, X., Huang, H., Guan, Y., Gong, Y., He, C.Y., Yi, X., Qi, M., Chen, Z.Y., Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women. Cancer Med. 6 (2017), 207–219.
104. Li, Y., Ohira, M., Zhou, Y., Xiong, T., Luo, W., Yang, C., Li, X., Gao, Z., Zhou, R., Nakamura, Y., Kamijo, T., Kaneko, Y., Taketani, T., Ueyama, J., Tajiri, T., Zhang, H., Wang, J., Yang, H., Yin, Y., Nakagawara, A., Genomic analysis-integrated whole-exome sequencing of neuroblastomas identifies genetic mutations in axon guidance pathway. Oncotarget, 2017, 10.18632/oncotarget.18079 [Epub ahead of print].
105. Di Meo, A., Pasic, M.D., Yousef, G.M., Proteomics and peptidomics: moving toward precision medicine in urological malignancies. Oncotarget 7 (2016), 52460–52474.
106. Zhou, L., Wang, K., Li, Q., Nice, E.C., Zhang, H., Huang, C., Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives. Expert Rev Proteomics 13 (2016), 367–381.
107. Myung, J.K., Sadar, M.D., Proteomics and prostate cancer. Thangadurai, D., Sangeetha, J., (eds.) GENOMICS and PROTEOMICS; Principles, Technologies, and Applications, 2015, Apple Academic Press, 143–174.
108. Ni, Y.H., Ding, L., Hu, Q.G., Hua, Z.C., Potential biomarkers for oral squamous cell carcinoma: proteomics discovery and clinical validation. Proteomics Clin. Appl. 9 (2015), 86–97.
109. Saraswat, M., Makitie, A., Agarwal, R., Joenvaara, S., Renkonen, S., Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics. Br. J. Cancer, 2017.
110. Zhu, J., Djukovic, D., Deng, L., Gu, H., Himmati, F., Abu Zaid, M., Chiorean, E.G., Raftery, D., Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring. Anal. Bioanal. Chem. 407 (2015), 7857–7863.
111. Jerzak, K.J., Laureano, M., Elsharawi, R., Kavsak, P., Chan, K.K., Dhesy-Thind, S.K., Zbuk, K., Targeted metabolomics in colorectal cancer: a strategic approach using standardized laboratory tests of the blood and urine. Hypoxia (Auckl) 5 (2017), 61–66.
112. Di Poto, C., Ferrarini, A., Zhao, Y., Varghese, R.S., Tu, C., Zuo, Y., Wang, M., Nezami Ranjbar, M.R., Luo, Y., Zhang, C., Desai, C.S., Shetty, K., Tadesse, M.G., Ressom, H.W., Metabolomic characterization of hepatocellular carcinoma in patients with liver cirrhosis for biomarker discovery. Cancer Epidemiol. Biomark. Prev. 26 (2017), 675–683.
113. Priolo, C., Pyne, S., Rose, J., Regan, E.R., Zadra, G., Photopoulos, C., Cacciatore, S., Schultz, D., Scaglia, N., McDunn, J., De Marzo, A.M., Loda, M., AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer. Cancer Res. 74 (2014), 7198–7204.
114. Rao, J.U., Engelke, U.F., Sweep, F.C., Pacak, K., Kusters, B., Goudswaard, A.G., Hermus, A.R., Mensenkamp, A.R., Eisenhofer, G., Qin, N., Richter, S., Kunst, H.P., Timmers, H.J., Wevers, R.A., Genotype-specific differences in the tumor metabolite profile of pheochromocytoma and paraganglioma using untargeted and targeted metabolomics. J. Clin. Endocrinol. Metab. 100 (2015), E214–22.
115. Ruggles, K.V., Krug, K., Wang, X., Clauser, K.R., Wang, J., Payne, S.H., Fenyo, D., Zhang, B., Mani, D.R., Methods, tools and current perspectives in proteogenomics. Mol. Cell. Proteomics 16 (2017), 959–981.
116. Fiore, L.D., Rodriguez, H., Shriver, C.D., Collaboration to accelerate proteogenomics cancer care: the Department of Veterans Affairs, Department of Defense, and the National Cancer Institute's Applied Proteogenomics OrganizationaL Learning and Outcomes (APOLLO) network. Clin. Pharmacol. Ther. 101 (2017), 619–621.
117. McAfee, A., Foster, L.J., Proteogenomics: recycling public data to improve genome annotations. Methods Enzymol. 585 (2017), 217–243.
118. Kroll, J.E., da Silva, V.L., de Souza, S.J., de Souza, G.A., A tool for integrating genetic and mass spectrometry-based peptide data: proteogenomics viewer: PV: a genome browser-like tool, which includes MS data visualization and peptide identification parameters. Bioessays, 39, 2017, 10.1002/bies.201700015 (Epub 2017 Jun 5).
119. Hernandez-Valladares, M., Vaudel, M., Selheim, F., Berven, F., Bruserud, O., Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers. Expert Rev. Proteomics 14 (2017), 649–663.
120. Rolland, D.C.M., Basrur, V., Jeon, Y.K., McNeil-Schwalm, C., Fermin, D., Conlon, K.P., Zhou, Y., Ng, S.Y., Tsou, C.C., Brown, N.A., Thomas, D.G., Bailey, N.G., Omenn, G.S., Nesvizhskii, A.I., Root, D.E., Weinstock, D.M., Faryabi, R.B., Lim, M.S., Elenitoba-Johnson, K.S.J., Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. Proc. Natl. Acad. Sci. U. S. A. 114 (2017), 6581–6586.
121. Chiou, S.H., Lee, K.T., Proteomic analysis and translational perspective of hepatocellular carcinoma: identification of diagnostic protein biomarkers by an onco-proteogenomics approach. Kaohsiung J. Med. Sci. 32 (2016), 535–544.
122. Bansal, N., Gupta, A., Sankhwar, S.N., Proteometabolomics of bladder cancer: current and future prospects. Cancer Biomark. 15 (2015), 339–348.
123. Vaiopoulou, A., Gazouli, M., Karikas, G.A., Pharmacogenomics: current applications and future prospects towards personalized therapeutics. J. BUON 18 (2013), 570–578.
124. Burt, T., Nandal, S., Pharmacometabolomics in early-phase clinical development. Clin. Transl. Sci. 9 (2016), 128–138.
125. Sarris, K., Komianou, A., Patrinos, G.P., Katsila, T., Application of the DruGeVar database in cancer genomics and pharmacogenomics. Public Health Genomics, 2017.
126. Bignucolo, A., De Mattia, E., Cecchin, E., Roncato, R., Toffoli, G., Pharmacogenomics of targeted agents for personalization of colorectal cancer treatment. Int. J. Mol. Sci., 18, 2017, 10.3390/ijms18071522.
127. Nath, A., Wang, J., Stephanie Huang, R., Pharmacogenetics and pharmacogenomics of targeted therapeutics in chronic myeloid leukemia. Mol. Diagn. Ther., 2017.
128. Nandal, S., Burt, T., Integrating pharmacoproteomics into early-phase clinical development: state-of-the-art, challenges, and recommendations. Int. J. Mol. Sci., 18, 2017, 10.3390/ijms18020448.
129. Beger, R.D., Dunn, W., Schmidt, M.A., Gross, S.S., Kirwan, J.A., Cascante, M., Brennan, L., Wishart, D.S., Oresic, M., Hankemeier, T., Broadhurst, D.I., Lane, A.N., Suhre, K., Kastenmuller, G., Sumner, S.J., Thiele, I., Fiehn, O., Kaddurah-Daouk, R., for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Metabolomics enables precision medicine: “a white paper, community perspective”. Metabolomics, 12, 2016, 149.
130. Miolo, G., Muraro, E., Caruso, D., Crivellari, D., Ash, A., Scalone, S., Lombardi, D., Rizzolio, F., Giordano, A., Corona, G., Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget 7 (2016), 39809–39822.
131. Kaddurah-Daouk, R., Weinshilboum, R., Pharmacometabolomics Research Network, Metabolomic signatures for drug response phenotypes: pharmacometabolomics enables precision medicine. Clin. Pharmacol. Ther. 98 (2015), 71–75.
132. Aboel Dahab, A., El-Hag, D., Moutamed, G.M., Aboel Dahab, S., Abuknesha, R., Smith, N.W., Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics. Cancer Chemother. Pharmacol. 78 (2016), 465–489.
133. Bodrova, T.A., Kostyushev, D.S., Antonova, E.N., Slavin, S., Gnatenko, D.A., Bocharova, M.O., Legg, M., Pozzilli, P., Paltsev, M.A., Suchkov, S.V., Introduction into PPPM as a new paradigm of public health service: an integrative view. EPMA J., 3(16), 2012 (5085-3-16).
134. Chambliss, A.B., Chan, D.W., Precision medicine: from pharmacogenomics to pharmacoproteomics. Clin. Proteomics, 13, 2016, 25.
135. Kantae, V., Krekels, E.H.J., Esdonk, M.J.V., Lindenburg, P., Harms, A.C., Knibbe, C.A.J., Van der Graaf, P.H., Hankemeier, T., Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics, 13(9), 2017 (016-1143-1. Epub 2016 Dec 19).
136. Neavin, D., Kaddurah-Daouk, R., Weinshilboum, R., Pharmacometabolomics informs pharmacogenomics. Metabolomics, 12, 2016, 121 (Epub 2016 Jul 1).
137. Ritchie, M.D., Holzinger, E.R., Li, R., Pendergrass, S.A., Kim, D., Methods of integrating data to uncover genotype-phenotype interactions. Nat. Rev. Genet. 16 (2015), 85–97.
138. Cheng, T., Zhan, X., Pattern recognition for predictive, preventive, and personalized medicine in cancer. EPMA J. 8 (2017), 51–60.
139. Chin, L., Hahn, W.C., Getz, G., Meyerson, M., Making sense of cancer genomic data. Genes Dev. 25 (2011), 534–555.
140. International Cancer Genome Consortium, Hudson, T.J., Anderson, W., Artez, A., Barker, A.D., Bell, C., Bernabe, R.R., Bhan, M.K., Calvo, F., Eerola, I., Gerhard, D.S., Guttmacher, A., Guyer, M., Hemsley, F.M., Jennings, J.L., Kerr, D., Klatt, P., Kolar, P., Kusada, J., Lane, D.P., Laplace, F., Youyong, L., Nettekoven, G., Ozenberger, B., Peterson, J., Rao, T.S., Remacle, J., Schafer, A.J., Shibata, T., Stratton, M.R., Vockley, J.G., Watanabe, K., Yang, H., Yuen, M.M., Knoppers, B.M., Bobrow, M., Cambon-Thomsen, A., Dressler, L.G., Dyke, S.O., Joly, Y., Kato, K., Kennedy, K.L., Nicolas, P., Parker, M.J., Rial-Sebbag, E., Romeo-Casabona, C.M., Shaw, K.M., Wallace, S., Wiesner, G.L., Zeps, N., Lichter, P., Biankin, A.V., Chabannon, C., Chin, L., Clement, B., de Alava, E., Degos, F., Ferguson, M.L., Geary, P., Hayes, D.N., Hudson, T.J., Johns, A.L., Kasprzyk, A., Nakagawa, H., Penny, R., Piris, M.A., Sarin, R., Scarpa, A., Shibata, T., van de Vijver, M., Futreal, P.A., Aburatani, H., Bayes, M., Botwell, D.D., Campbell, P.J., Estivill, X., Gerhard, D.S., Grimmond, S.M., Gut, I., Hirst, M., Lopez-Otin, C., Majumder, P., Marra, M., JD, McPherson, Nakagawa, H., Ning, Z., Puente, X.S., Ruan, Y., Shibata, T., Stratton, M.R., Stunnenberg, H.G., Swerdlow, H., Velculescu, V.E., Wilson, R.K., Xue, H.H., Yang, L., Spellman, P.T., Bader, G.D., Boutros, P.C., Campbell, P.J., Flicek, P., Getz, G., Guigo, R., Guo, G., Haussler, D., Heath, S., Hubbard, T.J., Jiang, T., Jones, S.M., Li, Q., Lopez-Bigas, N., Luo, R., Muthuswamy, L., Ouellette, B.F., Pearson, J.V., Puente, X.S., Quesada, V., Raphael, B.J., Sander, C., Shibata, T., Speed, T.P., Stein, L.D., Stuart, J.M., Teague, J.W., Totoki, Y., Tsunoda, T., Valencia, A., Wheeler, D.A., Wu, H., Zhao, S., Zhou, G., Stein, L.D., Guigo, R., Hubbard, T.J., Joly, Y., Jones, S.M., Kasprzyk, A., Lathrop, M., Lopez-Bigas, N., Ouellette, B.F., Spellman, P.T., Teague, J.W., Thomas, G., Valencia, A., Yoshida, T., Kennedy, K.L., Axton, M., Dyke, S.O., Futreal, P.A., Gerhard, D.S., Gunter, C., Guyer, M., Hudson, T.J., JD, McPherson, Miller, L.J., Ozenberger, B., Shaw, K.M., Kasprzyk, A., Stein, L.D., Zhang, J., Haider, S.A., Wang, J., Yung, C.K., Cros, A., Liang, Y., Gnaneshan, S., Guberman, J., Hsu, J., Bobrow, M., Chalmers, D.R., Hasel, K.W., Joly, Y., Kaan, T.S., Kennedy, K.L., Knoppers, B.M., Lowrance, W.W., Masui, T., Nicolas, P., Rial-Sebbag, E., Rodriguez, L.L., Vergely, C., Yoshida, T., Grimmond, S.M., Biankin, A.V., Bowtell, D.D., Cloonan, N., de Fazio, A., Eshleman, J.R., Etemadmoghadam, D., Gardiner, B.B., Kench, J.G., Scarpa, A., Sutherland, R.L., Tempero, M.A., Waddell, N.J., Wilson, P.J., JD, McPherson, Gallinger, S., Tsao, M.S., Shaw, P.A., Petersen, G.M., Mukhopadhyay, D., Chin, L., RA, DePinho, Thayer, S., Muthuswamy, L., Shazand, K., Beck, T., Sam, M., Timms, L., Ballin, V., Lu, Y., Ji, J., Zhang, X., Chen, F., Hu, X., Zhou, G., Yang, Q., Tian, G., Zhang, L., Xing, X., Li, X., Zhu, Z., Yu, Y., Yu, J., Yang, H., Lathrop, M., Tost, J., Brennan, P., Holcatova, I., Zaridze, D., Brazma, A., Egevard, L., Prokhortchouk, E., Banks, R.E., Uhlen, M., Cambon-Thomsen, A., Viksna, J., Ponten, F., Skryabin, K., Stratton, M.R., Futreal, P.A., Birney, E., Borg, A., Borresen-Dale, A.L., Caldas, C., Foekens, J.A., Martin, S., Reis-Filho, J.S., Richardson, A.L., Sotiriou, C., Stunnenberg, H.G., Thoms, G., van de Vijver, M., van't Veer, L., Calvo, F., Birnbaum, D., Blanche, H., Boucher, P., Boyault, S., Chabannon, C., Gut, I., Masson-Jacquemier, J.D., Lathrop, M., Pauporte, I., Pivot, X., Vincent-Salomon, A., Tabone, E., Theillet, C., Thomas, G., Tost, J., Treilleux, I., Calvo, F., Bioulac-Sage, P., Clement, B., Decaens, T., Degos, F., Franco, D., Gut, I., Gut, M., Heath, S., Lathrop, M., Samuel, D., Thomas, G., Zucman-Rossi, J., Lichter, P., Eils, R., Brors, B., Korbel, J.O., Korshunov, A., Landgraf, P., Lehrach, H., Pfister, S., Radlwimmer, B., Reifenberger, G., Taylor, M.D., von Kalle, C., Majumder, P.P., Sarin, R., Rao, T.S., Bhan, M.K., Scarpa, A., Pederzoli, P., Lawlor, R.A., Delledonne, M., Bardelli, A., Biankin, A.V., Grimmond, S.M., Gress, T., Klimstra, D., Zamboni, G., Shibata, T., Nakamura, Y., Nakagawa, H., Kusada, J., Tsunoda, T., Miyano, S., Aburatani, H., Kato, K., Fujimoto, A., Yoshida, T., Campo, E., Lopez-Otin, C., Estivill, X., Guigo, R., de Sanjose, S., Piris, M.A., Montserrat, E., Gonzalez-Diaz, M., Puente, X.S., Jares, P., Valencia, A., Himmelbauer, H., Quesada, V., Bea, S., Stratton, M.R., Futreal, P.A., Campbell, P.J., Vincent-Salomon, A., Richardson, A.L., Reis-Filho, J.S., van de Vijver, M., Thomas, G., Masson-Jacquemier, J.D., Aparicio, S., Borg, A., Borresen-Dale, A.L., Caldas, C., Foekens, J.A., Stunnenberg, H.G., van't Veer, L., Easton, D.F., Spellman, P.T., Martin, S., Barker, A.D., Chin, L., Collins, F.S., Compton, C.C., Ferguson, M.L., Gerhard, D.S., Getz, G., Gunter, C., Guttmacher, A., Guyer, M., Hayes, D.N., Lander, E.S., Ozenberger, B., Penny, R., Peterson, J., Sander, C., Shaw, K.M., Speed, T.P., Spellman, P.T., Vockley, J.G., Wheeler, D.A., Wilson, R.K., Hudson, T.J., Chin, L., Knoppers, B.M., Lander, E.S., Lichter, P., Stein, L.D., Stratton, M.R., Anderson, W., Barker, A.D., Bell, C., Bobrow, M., Burke, W., Collins, F.S., Compton, C.C., De Pinho, R.A., Easton, D.F., Futreal, P.A., Gerhard, D.S., Green, A.R., Guyer, M., Hamilton, S.R., Hubbard, T.J., Kallioniemi, O.P., Kennedy, K.L., Ley, T.J., Liu, E.T., Lu, Y., Majumder, P., Marra, M., Ozenberger, B., Peterson, J., Schafer, A.J., Spellman, P.T., Stunnenberg, H.G., Wainwright, B.J., Wilson, R.K., Yang, H., International network of cancer genome projects. Nature 464 (2010), 993–998.
141. Creixell, P., Reimand, J., Haider, S., Wu, G., Shibata, T., Vazquez, M., Mustonen, V., Gonzalez-Perez, A., Pearson, J., Sander, C., Raphael, B.J., Marks, D.S., Ouellette, B.F.F., Valencia, A., Bader, G.D., Boutros, P.C., Stuart, J.M., Linding, R., Lopez-Bigas, N., Stein, L.D., Mutation Consequences and Pathway Analysis Working Group of the International Cancer Genome Consortium. Pathway and network analysis of cancer genomes. Nat. Methods 12 (2015), 615–621.
142. Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M., The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45 (2013), 1113–1120.
143. Cline, M.S., Craft, B., Swatloski, T., Goldman, M., Ma, S., Haussler, D., Zhu, J., Exploring TCGA pan-cancer data at the UCSC cancer genomics browser. Sci Rep, 3, 2013, 2652.
144. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative.
145. Wang, X., Cancer Moonshot 2020: a new march of clinical and translational medicine. Clin. Transl. Med., 5(11), 2016 (016-0091-8. Epub 2016 Mar 10).
146. Mayer, D.K., Fuld, Nasso S., Cancer moonshot: what it means for patients. Clin. J. Oncol. Nurs. 21 (2017), 141–142.
147. Hsu, E.R., Klemm, J.D., Kerlavage, A.R., Kusnezov, D., Kibbe, W.A., Cancer moonshot data and technology team: enabling a National Learning Healthcare System for cancer to unleash the power of data. Clin. Pharmacol. Ther. 101 (2017), 613–615.
148. Kahi, C.J., A colorectal cancer moonshot. Clin. Gastroenterol. Hepatol. 15 (2017), 910–912.